Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 232

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo

Luo, Yan, Shoemaker, Alexander R., Liu, Xuesong, Woods, Keith W., Thomas, Sheela A., de Jong, Ron, Han, Edward K., Li, Tongmei, Stoll, Vincent S., Powlas, Jessica A., Oleksijew, Anatol, Mitten, Michael J., Shi, Yan, Guan, Ran, McGonigal, Thomas P., Klinghofer, Vered, Johnson, Eric F., Leverson, Joel D., Bouska, Jennifer J., Mamo, Mulugeta, Smith, Richard A., Gramling-Evans, Emily E., Zinker, Bradley A., Mika, Amanda K., Nguyen, Phong T., Oltersdorf, Tilman, Rosenberg, Saul H., Li, Qun, Giranda, Vincent L. · 2005 · Molecular Cancer Therapeutics

Abstract

The Akt kinases are central nodes in signal transduction pathways that are important for cellular transformation and tumor progression. We report the development of a series of potent and selective indazole-pyridine based Akt inhibitors. These compounds, exemplified by A-443654 (Ki = 160 pmol/L versus Akt1), inhibit Akt-dependent signal transduction in cells and in vivo in a dose-responsive manner. In vivo, the Akt inhibitors slow the progression of tumors when used as monotherapy or in combination with paclitaxel or rapamycin. Tumor growth inhibition was observed during the dosing interval, and the tumors regrew when compound administration was ceased. The therapeutic window for these compounds is narrow. Efficacy is achieved at doses ∼2-fold lower than the maximally tolerated doses. Consistent with data from knockout animals, the Akt inhibitors induce an increase in insulin secretion. They also induce a reactive increase in Akt phosphorylation. Other toxicities observed, including malaise and weight loss, are consistent with abnormalities in glucose metabolism. These data show that direct Akt inhibition may be useful in cancer therapy, but significant metabolic toxicities are likely dose limiting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-05-0005

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 232

Metadata

Authors
Luo, Y., Shoemaker, A. R., Liu, X., Woods, K. W., Thomas, S. A., de Jong, R., Han, E. K., Li, T., Stoll, V. S., Powlas, J. A., Oleksijew, A., Mitten, M. J., Shi, Y., Guan, R., McGonigal, T. P., Klinghofer, V., Johnson, E. F., Leverson, J. D., Bouska, J. J., Mamo, M., Smith, R. A., Gramling-Evans, E. E., Zinker, B. A., Mika, A. K., Nguyen, P. T., Oltersdorf, T., Rosenberg, S. H., Li, Q., & Giranda, V. L.
Venue
Molecular Cancer Therapeutics
Published
2005-06-01
Volume
4
Issue
6
Pages
977-986
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2112842133
Cited by
232
References
2
FWCI
8.87
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. https://app.cochat.ai/papers/10.1158/1535-7163.mct-05-0005
The paper
Luo, Y., Shoemaker, A. R., Liu, X., Woods, K. W., Thomas, S. A., de Jong, R., Han, E. K., Li, T., Stoll, V. S., Powlas, J. A., Oleksijew, A., Mitten, M. J., Shi, Y., Guan, R., McGonigal, T. P., Klinghofer, V., Johnson, E. F., Leverson, J. D., Bouska, J. J., . . . Giranda, V. L. (2005). Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-05-0005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.